Eltropag 50 mg (Eltrombopag) Tablets

Eltropag 50 contains eltrombopag, an oral thrombopoietin receptor agonist that helps stimulate the body's natural production of platelets. It is commonly prescribed for patients experiencing low platelet counts due to chronic immune thrombocytopenia (ITP), severe aplastic anemia, or thrombocytopenia associated with certain medical conditions. By increasing platelet levels, the medicine helps reduce the risk of excessive bleeding, bruising, and other complications related to thrombocytopenia. Eltropag 50 supports healthy blood clotting function and may improve the quality of life for patients who require long-term platelet management. Regular medical monitoring is recommended to ensure safe and effective treatment outcomes.

Each film-coated tablet of Eltropag 50 contains Eltrombopag Olamine equivalent to Eltrombopag 50 mg as the active ingredient. Eltrombopag works by stimulating thrombopoietin receptors in the bone marrow, encouraging the production and maturation of platelets. The formulation also includes carefully selected pharmaceutical excipients that contribute to tablet stability, dissolution, and overall product performance. Manufactured according to recognized pharmaceutical quality standards, the product is designed to provide consistent potency, reliability, and therapeutic effectiveness throughout its shelf life. Patients should use the medicine only under the supervision of a qualified healthcare professional.

The appropriate dosage of Eltropag 50 should always be determined by a physician based on the patient's age, diagnosis, platelet count, liver function, and response to therapy. The tablet is administered orally and is generally taken once daily, preferably at the same time each day to maintain consistent blood levels. For optimal absorption, it should be taken on an empty stomach or according to healthcare provider instructions. The dosage may be adjusted periodically depending on platelet count monitoring and clinical response. Patients should swallow the tablet whole with water and avoid crushing or chewing it unless specifically advised. Routine laboratory assessments, including platelet counts and liver function tests, may be required during treatment. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. Do not take a double dose to compensate for a missed tablet. Treatment should not be stopped or modified without medical guidance, as sudden changes may affect platelet levels and treatment effectiveness.